Insights & Resources

Discover how outsourcing in pharmaceutical manufacturing enhances quality, ensures compliance and mitigates risks in a rapidly evolving industry.

Learn how HMRC's guidelines impact transfer pricing for life sciences and other multinationals and how to mitigate risks and ensure compliance.

Digital assets have evolved at an incredible rate, and taxation rules are starting to catch up. We take a look at the potential changes.

The SEC’s new regulations for safeguarding crypto assets and the administration’s executive order are changing the landscape for digital assets.

J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.

KPMG has released their 2024 biopharma report detailing the challenges and opportunities for pharma companies moving forward into the new year.

Weaver’s overview of the SEC’s 2025 examination priorities describe practices by investment advisers and others that may come under SEC review.

The SEC’s approval of cryptocurrencies for trading means that taxpayers need to know the specific tax consequences associated with them.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.

The IRS released final regulations requiring “custodial” digital asset brokers to report digital asset sales and exchanges with little time to prepare.

Weaver’s second quarterly Accounting and SEC Update of 2024 covered stock compensation and other standards updates, filer status assessments and recent SEC/ PCAOB enforcement actions.